Safety of Urate-Lowering Therapies Managing the Risks to Gain the Benefits

被引：15

作者：

Keenan, Robert T. ^{[1
,2
,3
]}

机构：

[1] Duke Specialty Infus Ctr, Duke Gout & Crystal Arthropathies Clin, Durham, NC 27710 USA

[2] Duke Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Durham, NC 27710 USA

[3] Duke Univ, Med Ctr, Durham, NC USA

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2012年 / 38卷 / 04期

关键词：

Gout; Allopurinol; Febuxostat; Pelgoticase; Safety; STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; PRACTICE RESEARCH DATABASE; US GENERAL-POPULATION; SERUM URATE; HYPERSENSITIVITY SYNDROME; CARDIOVASCULAR-DISEASE; PLASMA OXYPURINOL; ADVERSE-REACTIONS; XANTHINE-OXIDASE;

D O I：

10.1016/j.rdc.2012.08.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Gout is a metabolic disorder of purine metabolism and uric acid elimination. Over time, acute gout can develop into a chronic, disabling arthropathy, often associated with multiple comorbidities. Gout patients have often been undertreated, partly because of the clinician's perceived risks of a therapy outweighing its potential benefits. The approval of new therapies to treat hyperuricemia in gout has led to a new understanding of gout management and medication safety regarding new and old therapies. This review focuses on potential safety issues of currently available urate-lowering therapies and outlines strategies to minimize risks so their benefits can be reached.

引用

页码：663 / +

页数：19

共 50 条

[21] Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials
Fan, Meida
Liu, Jian
Zhao, Bingcheng
Wu, Xinyu
Li, Xuefeng
Gu, Jieruo
Schlesinger, Naomi
CLINICAL RHEUMATOLOGY, 2021, 40 (02) : 683 - 692
[22] Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials
Meida Fan
Jian Liu
Bingcheng Zhao
Xinyu Wu
Xuefeng Li
Jieruo Gu
Naomi Schlesinger
Clinical Rheumatology, 2021, 40 : 683 - 692
[23] Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults
Singh, Jasvinder A.
Cleveland, John D.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (08) : 1243 - +
[24] Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting
Lee, Sunggun
So, Min Wook
MODERN RHEUMATOLOGY, 2016, 26 (06) : 950 - 955
[25] Use of urate-lowering therapies is not associated with an increased risk of incident dementia in older adults
Lee, Young Ho
Song, Gwan Gyu
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (10)
[26] Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout
Yen, Fu-Shun
Hsu, Chih-Cheng
Li, Hsin-Lun
Wei, James Cheng-Chung
Hwu, Chii-Min
PLOS ONE, 2020, 15 (06):
[27] The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
Michael A Becker
H Ralph Schumacher
Luis R Espinoza
Alvin F Wells
Patricia MacDonald
Eric Lloyd
Christopher Lademacher
Arthritis Research & Therapy, 12 (2):
[28] The urate-lowering Efficacy and Safety of Febuxostat in the Treatment Hyperuricemia of Gout: The CONFIRMS trial
Dejaco, C.
Duftner, C.
JOURNAL FUR MINERALSTOFFWECHSEL, 2010, 17 (02): : 84 - 84
[29] The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
Becker, Michael A.
Schumacher, H. Ralph
Espinoza, Luis R.
Wells, Alvin F.
MacDonald, Patricia
Lloyd, Eric
Lademacher, Christopher
ARTHRITIS RESEARCH & THERAPY, 2010, 12 (02)
[30] Analyses of The Urate-lowering Effects by Zotepine and Chlorprothixene
Onizawa, Nobuyuki
Izeki, Tatou
Hori, Takayuki
Otani, Naoyuki
Ouchi, Motoshi
Hasegawa, Hajime
Anzai, Naohiko
FASEB JOURNAL, 2015, 29

← 1 2 3 4 5 →